Q3 2019 EPS Estimates for Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Lowered by B. Riley

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) – Research analysts at B. Riley reduced their Q3 2019 EPS estimates for shares of Dicerna Pharmaceuticals in a report issued on Monday, August 12th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings of ($0.36) per share for the quarter, down from their previous estimate of ($0.35). B. Riley has a “Buy” rating and a $24.00 price target on the stock. B. Riley also issued estimates for Dicerna Pharmaceuticals’ Q4 2019 earnings at ($0.37) EPS, FY2019 earnings at ($1.79) EPS, FY2020 earnings at ($1.96) EPS, FY2021 earnings at ($2.02) EPS, FY2022 earnings at ($1.39) EPS and FY2023 earnings at ($0.99) EPS.

A number of other research firms have also recently issued reports on DRNA. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, June 11th. Citigroup boosted their price objective on shares of Dicerna Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Wednesday, July 3rd. BidaskClub upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday. Chardan Capital reiterated a “buy” rating and set a $18.00 price target on shares of Dicerna Pharmaceuticals in a research report on Tuesday. Finally, Cowen reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, July 2nd. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $21.57.

DRNA stock opened at $14.59 on Wednesday. The firm’s 50-day moving average price is $14.44 and its two-hundred day moving average price is $13.24. Dicerna Pharmaceuticals has a 12-month low of $9.31 and a 12-month high of $17.98. The stock has a market capitalization of $965.24 million, a price-to-earnings ratio of -12.16 and a beta of 2.16. The company has a current ratio of 5.00, a quick ratio of 5.00 and a debt-to-equity ratio of 0.01.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Dicerna Pharmaceuticals had a negative net margin of 737.93% and a negative return on equity of 48.98%. The firm had revenue of $5.68 million during the quarter, compared to analysts’ expectations of $10.95 million.

In related news, Director Bain Capital Life Sciences Inv sold 1,600,000 shares of the business’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $12.50, for a total transaction of $20,000,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 21.28% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp raised its position in Dicerna Pharmaceuticals by 17.6% during the fourth quarter. Bank of New York Mellon Corp now owns 218,093 shares of the biopharmaceutical company’s stock valued at $2,331,000 after buying an additional 32,652 shares during the period. Northern Trust Corp raised its position in Dicerna Pharmaceuticals by 15.9% during the fourth quarter. Northern Trust Corp now owns 647,143 shares of the biopharmaceutical company’s stock valued at $6,917,000 after buying an additional 88,559 shares during the period. Geode Capital Management LLC raised its position in Dicerna Pharmaceuticals by 24.4% during the fourth quarter. Geode Capital Management LLC now owns 554,957 shares of the biopharmaceutical company’s stock valued at $5,932,000 after buying an additional 109,012 shares during the period. Bank of America Corp DE raised its position in Dicerna Pharmaceuticals by 30.3% during the fourth quarter. Bank of America Corp DE now owns 10,596 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 2,465 shares during the period. Finally, Metropolitan Life Insurance Co. NY raised its position in Dicerna Pharmaceuticals by 450.0% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 18,469 shares of the biopharmaceutical company’s stock valued at $197,000 after buying an additional 15,111 shares during the period. Institutional investors and hedge funds own 85.08% of the company’s stock.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Recommended Story: Cryptocurrencies

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.